{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:10:47Z","timestamp":1778152247385,"version":"3.51.4"},"reference-count":0,"publisher":"Il Pensiero Scientifico Editore","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:p>Summary. Gastric cancer (GC) and esophagogastric junction cancer (EGJC) impose a severe global burden, with traditional treatments plagued by poor efficacy, high toxicity, and chemoresistance. Claudin 18.2 (CLDN18.2), a highly tissue-specific target, is abnormally overexpressed in GC\/EGJC with limited overlap with HER2 positivity or PD-L1 CPS \u22655, making it ideal for precision therapy. Zolbetuximab, a CLDN18.2-targeted ADC, exerts anti-tumor effects via \u201ctargeted binding-endocytosis-MMAE release\u201d, reducing systemic toxicity versus traditional chemotherapy. Pivotal trials (MONO, FAST, SPOTLIGHT\/GLOW, ILUSTRO) confirmed its monotherapy efficacy and superior PFS\/OS when combined with chemotherapy (EOX, mFOLFOX6, CAPOX) in CLDN18.2-positive (\u226570% staining), HER2-negative advanced GC\/EGJC patients, with manageable safety. SPOTLIGHT\/GLOW laid the foundation for its first-line approval. Post-approval, it may expand to other CLDN18.2-positive tumors and neoadjuvant\/adjuvant therapy, with combination regimen optimization. However, MMAE\u2019s long-term cumulative toxicity, uncertain safety in special populations, and rare severe adverse reactions require real-world validation. This review systematically summarizes zolbetuximab\u2019s research progress, providing a reference for clinical application and future studies.<\/jats:p>","DOI":"10.1701\/4698.47106","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:18:15Z","timestamp":1778149095000},"source":"Crossref","is-referenced-by-count":0,"title":["Zolbetuximab: research progress and prospects in the treatment of gastric and gastroesophageal junction cancer targeting claudin 18.2"],"prefix":"10.1701","volume":"117","author":[{"given":"Shu-Wei","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Hao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Chun","family":"Leng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"55112","container-title":["Recenti Progressi in Medicina"],"original-title":[],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:18:16Z","timestamp":1778149096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.recentiprogressi.it\/articoli.php?archivio=yes&vol_id=4698&id=47106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1701\/4698.47106","relation":{},"ISSN":["0034-1193"],"issn-type":[{"value":"0034-1193","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}